May 02, 2017

Boehringer Ingelheim Celebrates a Decade of Difference

More than 500,000 dogs with CHF have been given the opportunity for increased longevity and improved quality of life with Vetmedin® (pimobendan)*

Duluth, GA – April 26, 2017 – April 30 marks the 10th anniversary of the U.S. launch of Vetmedin® (pimobendan) by Boehringer Ingelheim (BI), a global leader in the animal health industry. Over the past 10 years, more than a quarter of a billion doses have been administered to a half million dogs with CHF, giving those dogs the opportunity for better days and longer lives.[1]

“My first experience with VETMEDIN was as a vet student. I prescribed it throughout my residency and, as a practicing cardiologist, I continue to use it today,” said Danielle Laughlin, DVM, DACVIM-Cardiology, a veterinary cardiologist with BluePearl Veterinary Specialists in Atlanta. “The first criteria for any medication is efficacy. The dogs who receive VETMEDIN as part of a CHF treatment plan seem to feel perkier, have more energy and, when their heart failure is well-controlled, have a good quality of life. Additionally, VETMEDIN is practical to give, which is important for compliance. I personally haven’t seen issues with owners administering VETMEDIN.”

VETMEDIN was developed by scientists at Boehringer Ingelheim and has been at the center of some of the largest veterinary cardiology trials ever conducted. It was first marketed in Europe in 1999 and received U.S. FDA approval on April 30, 2007.

“Since its launch, VETMEDIN has revolutionized veterinary cardiac care,” said Michael Hamby, head of the U.S. Pet Vet Business for Boehringer Ingelheim. “Veterinary professionals can be confident prescribing VETMEDIN because it is manufactured and supported by the company that developed it and has deep scientific experience with this medication.”


“When she was around 12, Susie started coughing a little bit. I brought her to our vet who took an X-ray and said that Susie had an enlarged heart,” said Donna Robinson of Atlanta, owner of Susie, a 13-year-old Cairn Terrier. “As the coughing became worse, our vet suggested we take her to a specialist, which is how we met Dr. Laughlin who diagnosed Susie with congestive heart failure.”

“It was heartbreaking. Susie is like one of my kids. I’ve had her since she was about 2 years old,” Robinson added. “The diagnosis was very scary. I really thought I was going to lose her. Dr. Laughlin prescribed a treatment plan, and one of the medications was VETMEDIN. Susie’s turnaround in just two days was amazing.”

“I want to say thank you to the makers of VETMEDIN for this medication. There’s a big difference in Susie now. It’s like she came back to life.”                  

More information on VETMEDIN is available at



[1] Reference: 1. Lombard CW, Jöns O, Bussadori CM; for the VetSCOPE Study. Clinical efficacy
of pimobendan versus benazepril for the treatment of acquired atrioventricular valvular disease in dogs. J Am Anim Hosp Assoc. 2006;42(4):249–261.

*The number of doses administered and the number of dogs treated are approximate based on calculations from the number of units sold from 2007 to July 2016.



Use only in dogs with clinical evidence of heart failure. The safety of VETMEDIN has not been established in dogs with asymptomatic heart disease or in heart failure caused by etiologies other than atrioventricular valvular insufficiency or dilated cardiomyopathy. For complete product information, click here.  

About Boehringer Ingelheim Animal Health


In January 2017, Merial became part of the Boehringer Ingelheim group. As the second largest animal health business in the world, Boehringer Ingelheim is committed to making the industry even better at improving animal health. With more than 10,000 employees worldwide, Boehringer Ingelheim Animal Health has products available in more than 150 markets and a global presence in 99 countries. For more information about Boehringer Ingelheim Animal Health, click here.